SOLASIA-PHARMA
30.6.2021 10:00:07 CEST | Business Wire | Press release
Solasia Pharma K.K. (TSE: 4597, Headquarters: Tokyo, Japan, President & CEO: Yoshihiro Arai, hereinafter “Solasia”) today announced submission of a New Drug Application (NDA) for its new anti-cancer drug darinaparsin (generic name, development code: SP-02) as a treatment for relapsed or refractory peripheral T-cell lymphoma to the Ministry of Health, Labour and Welfare (MHLW). Based on positive results of R&D on darinaparsin, centered primarily on the results of the Asian Multinational Phase 2 Study (study results released in June 2020), Solasia filed an NDA for the drug with the regulatory authority in Japan ahead of anywhere else in the world.
Solasia expects to obtain regulatory approval in 2022 and to also launch in the same year. If approved and launched, darinaparsin would be the third drug Solasia successfully developed and brought to market since its founding and is expected to contribute to the treatment of PTCL.
Mr. Yoshihiro Arai, President and CEO of Solasia, commented as follows:
“No standard treatment has been established for relapsed or refractory PTCL as of yet. I firmly believe that darinaparsin, with its novel mechanism of action that differs from those of already approved drugs, will contribute to patients and healthcare providers at clinical sites as a new treatment option for relapsed or refractory PTCL. Since founding, Solasia has conducted R&D on five pipeline drugs. Of the five, we have successfully developed and brought to market two drugs, i.e., began providing them to patients, and today, we submitted an NDA for our first anti-cancer drug. Under our mission to provide patients with ‘Better Medicine for a Brighter Tomorrow’, we will continue aiming to contribute to patients’ treatment and enhanced quality of life. ”
About darinaparsin (SP-02)
Darinaparsin, an organoarsenic compound with anticancer activity, is a novel mitochondrial-targeted agent being developed for the treatment of various hematologic and solid tumors. The proposed mechanism of action of the drug involves the disruption of mitochondrial function, increased production of reactive oxygen species, and modulation of intracellular signal transduction pathways. Darinaparsin is believed to exert anticancer effect by inducing cell cycle arrest and apoptosis. Darinaparsin has been granted orphan drug designation in the US and EU.
For more information, please visit at https://solasia.co.jp/en/pipeline/sp-02.html
About Asian Multinational Phase 2 Study
The Asian Multinational Phase 2 Study was a multinational, multicenter, single-arm, open-label, non-randomized study to evaluate the efficacy and safety of darinaparsin monotherapy in patients with relapsed or refractory PTCL conducted in Japan, Korea, Taiwan, and Hong Kong. (CT.gov Identifier: NCT02653976).
Solasia plans to present the results of the study at an international academic conference to be held in the near future.
About peripheral T-cell lymphoma (PTCL)
Please visit at https://solasia.co.jp/en/pipeline/sp-02.html
About Solasia
Please visit at https://solasia.co.jp/en/
View source version on businesswire.com: https://www.businesswire.com/news/home/20210630005395/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AMCS Appoints Richard Humphrey as Chief Product and Technology Officer9.9.2026 15:00:00 CEST | Press release
Industrial software executive to lead global product strategy and accelerate AI innovation AMCS, a leading technology provider for the waste and recycling industry, today announced the appointment of Richard Humphrey as Chief Product and Technology Officer. Based in Boston, Humphrey will lead the company’s global product organisation. Humphrey brings more than 25 years of experience developing software for construction and other complex industrial environments. He joins AMCS as the company deepens its focus on waste and recycling and expands the role of AI across its platform. Most recently, Humphrey served as Chief Product and Technology Officer at Contruent, where he led product strategy for a construction cost-management platform used on major capital programmes. He previously held vice president roles at Bentley Systems and B2W Software. Earlier in his career, he spent more than a decade at Autodesk, where he led its Civil Design and Construction software business as Senior Directo
BBH Launches a New Technology Business, Braid, Solving for Intelligent Data Transformation9.9.2026 14:45:00 CEST | Press release
Braid’s agentic AI platform is purpose-built for financial services firms who need to transform, connect, and manage their data with confidence Brown Brothers Harriman (BBH) today announced the launch of a new technology affiliate, Braid LLC, focused on solving enterprise data transformation for financial services. Braid offers an AI-native data transformation platform that gives firms a scale solution to transform, connect, and manage their data with confidence. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260909294398/en/ Braid empowers teams to build, automate, and oversee reliable production-grade data transformations in a fraction of the time typically required today. Instead of requiring engineers to build data automations, Braid allows business users to describe their needs in natural language that AI agents use to build intelligent data transformations that are transparent and fully auditable. Braid’s enterprise-gr
LTM Collaborates with IBM and Red Hat on Lightwell to Advance AI-Driven Open-Source Software Remediation9.9.2026 14:30:00 CEST | Press release
Strengthens software supply chains by helping enterprises transform vulnerability discovery into scalable remediation outcomes LTM, the Business Creativity partner to the world's largest enterprises, today announced that it has collaborated with IBM and Red Hat on Lightwell to help enterprises safeguard the open-source software supply chain through AI-driven vulnerability remediation. As AI accelerates the discovery of software vulnerabilities, organizations must move beyond detection-focused approaches and adopt enterprise-scale remediation strategies that enable rapid risk mitigation without disrupting business-critical applications. Lightwell’s approach of delivering validated fixes for production environments aligns with LTM's aim of helping customers build secure, resilient, and operationally efficient software supply chains. By combining AI-powered remediation capabilities with enterprise-grade validation and deployment support, Lightwell aims to help organizations address securi
New England Journal of Medicine Publishes Data from Phase 3 Studies Demonstrating Oveporexton (ORZEYFUL) Improved the Full Range of Narcolepsy Type 1 Symptoms and Quality of Life9.9.2026 14:24:00 CEST | Press release
Data Demonstrated Significant and Clinically Meaningful Improvements with the Potential to Redefine Narcolepsy Type 1 (NT1) Care Beyond Individual Symptoms Oveporexton was Generally Well-Tolerated with Safety Profile Consistent with Previous Clinical Studies Oveporexton is the First and Only Approved Orexin Agonist Designed to Treat the Underlying Cause of NT1 and is Now Approved in the U.S., China and Japan, with Additional Regulatory Submissions Underway Takeda (TSE:4502/NYSE:TAK) announced that the New England Journal of Medicine published results from two Phase 3 studies evaluating oveporexton (ORZEYFUL), an oral orexin receptor 2 (OX2R) agonist, in people with narcolepsy type 1 (NT1).1 Oveporexton is the first and only medicine to treat the underlying cause of NT1. "People living with narcolepsy type 1 face persistent symptoms across the day and night, which can impact many aspects of daily life,” said Emmanuel Mignot, M.D., Ph.D., principal investigator for the FirstLight (TAK-86
ZincFive Launches Next-Generation BMS, Setting a New Standard for Nickel-Zinc Battery Management9.9.2026 14:05:00 CEST | Press release
Purpose-built Battery Management System (BMS) streamlines installation and supports the evolving power demands of AI data centers ZincFive®, the leader in nickel-zinc (NiZn) battery-based solutions for immediate power applications, today launched the ZincFive BMS, a next-generation battery management system purpose-built for its NiZn chemistry, designed and assembled in the U.S. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260909653032/en/ The ZincFive BMS ships standard with every ZincFive BC Series UPS Battery Cabinets, serving as the primary interface for data center operators, UPS OEM partners, and system integrators to monitor and manage ZincFive’s technology. Built on years of experience managing NiZn in real-world data center environments, ZincFive engineered the BMS around the unique characteristics of its NiZn chemistry, rather than adapting a platform designed for lithium-ion or lead-acid batteries. The result is
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom